Molecular mechanisms underlying rat mesenteric artery vasorelaxation induced by the nitric oxide-independent soluble guanylyl cyclase stimulators BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl] pyrimidin-4-ylamine] and YC-1 [3-(5′-hydroxymethyl-2′-furyl)-1- benzyl indazole]

Journal of Pharmacology and Experimental Therapeutics

Volumn 317, Issue 1, 2006, Pages 258-266

  Teixeira, Cleber E ^a   Priviero, Fernanda B M ^b   Webb, R Clinton ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

^b UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)INDAZOLE; 1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 2 (4 CARBOXYPHENYL) 4,4,5,5 TETRAMETHYLIMIDAZOLINE 1 OXYL 3 OXIDE; 2',5' DIDEOXYADENOSINE; 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDIN 4 YLAMINE; APAMIN; ATRIAL NATRIURETIC FACTOR; BAY 41 2272; CALYCULIN A; CHARYBDOTOXIN; CYCLIC GMP; CYCLOPIAZONIC ACID; GLIBENCLAMIDE; GUANYLATE CYCLASE ACTIVATOR; IBERIOTOXIN; N(G) NITROARGININE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; OUABAIN; PHENYLEPHRINE; PHOSPHODIESTERASE V INHIBITOR; POTASSIUM CHANNEL BLOCKING AGENT; PYRIMIDINE DERIVATIVE; ROLIPRAM; SILDENAFIL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; MALE; MESENTERIC ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; VASOCONSTRICTION; VASODILATATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; ENZYME ACTIVATORS; GUANYLATE CYCLASE; INDAZOLES; MALE; MESENTERIC ARTERY, SUPERIOR; NITRIC OXIDE; PYRAZOLES; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION;

EID: 33645126637     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.105.095752     Document Type: Article

References (38)

1. Archer SL, Huang JM, Hampl V, Nelson DP, Shultz PJ, and Weir EK (1994) Nitric oxide and cGMP cause vasorelaxation by activation of a charybdotoxin-sensitive K channel by cGMP-dependent protein kinase. Proc Natl Acad Sci USA 91:7583-7587.
2. Baracat JS, Teixeira CE, Okuyama CE, Priviero FB, Faro R, Antunes E, and De Nucci G (2003) Relaxing effects induced by the soluble guanylyl cyclase stimulator BAY 41-2272 in human and rabbit corpus cavernosum. Eur J Pharmacol 477:163-169.
3. Bawankule DU, Sathishkumar K, Sardar KK, Chanda D, Krishna AV, Prakash VR, and Mishra SK (2005) BAY 41-2272 [5-cyclopropyl-2-[1-(2-fluoro-benzyl)-1H- pyrazolo[3,4-b]pyridine-3-yl]pyrimidin-4-ylamine]-induced dilation in ovine pulmonary artery: role of sodium pump. J Pharmacol Exp Ther 314:207-213.
4. Becker EM, Schmidt P, Schramm M, Schroder H, Walter U, Hoenicka M, Gerzer R, and Stasch JP (2000) The vasodilator-stimulated phosphoprotein (VASP): target of YC-1 and nitric oxide effects in human and rat platelets. J Cardiovasc Pharmacol 35:390-397.
5. Boerrigter G, Costello-Boerrigter LC, Cataliotti A, Tsuruda T, Harty GJ, Lapp H, Stasch JP, and Burnett JC Jr (2003) Cardiorenal and humoral properties of a novel direct soluble guanylate cyclase stimulator BAY 41-2272 in experimental congestive heart failure. Circulation 107:686-689.
6. Burkhardt M, Glazova M, Gambaryan S, Vollkommer T, Butt E, Bader B, Heermeier K, Lincoln TM, Walter U, and Palmetshofer A (2000) KT5823 inhibits cGMP-dependent protein kinase activity in vitro but not in intact human platelets and rat mesangial cells. J Biol Chem 275:33536-33541.
7. Butt E, Eigenthaler M, and Genieser HG (1994) (Rp)-8-pCPT-cGMPS, a novel cGMP-dependent protein kinase inhibitor. Eur J Pharmacol 269:265-268.
8. Deruelle P, Grover TR, Storme L, and Abman SH (2005) Effects of BAY 41-2272, a soluble guanylate cyclase activator, on pulmonary vascular reactivity in the ovine fetus. Am J Physiol 288:L727-L733.
9. Dimmeler S, Fleming I, Fisslthaler B, Hermann C, Busse R, and Zeiher AM (1999) Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature (Lond) 399:601-605.
10. Dostmann WR, Taylor MS, Nickl CK, Brayden JE, Frank R, and Tegge WJ (2000) Highly specific, membrane-permeant peptide blockers of cGMP-dependent protein kinase Iα inhibit NO-induced cerebral dilation. Proc Natl Acad Sci USA 97:14772-14777.
11. Evgenov OV, Ichinose F, Evgenov NV, Gnoth MJ, Falkowski GE, Chang Y, Bloch KD, and Zapol WM (2004) Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110:2253-2259.
12. Friebe A and Koesling D (2003) Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 93:96-105.
13. Friebe A, Mullershausen F, Smolenski A, Walter U, Schultz G, and Koesling D (1998) YC-1 potentiates nitric oxide- and carbon monoxide-induced cyclic GMP effects in human platelets. Mol Pharmacol 54:962-967.
14. Galle J, Zabel U, Hubner U, Hatzelmann A, Wagner B, Wanner C, and Schmidt HH (1999) Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br J Pharmacol 127:195-203.
15. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, and Mayer B (1995) Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48:184-188.
16. Grider JR (1993) Interplay of VIP and nitric oxide in regulation of the descending relaxation phase of peristalsis. Am J Physiol 264:G334-G340.
17. Hobbs AJ (1997) Soluble guanylate cyclase: the forgotten sibling. Trends Pharmacol Sci 18:484-491.
18. Hoenicka M, Becker EM, Apeler H, Sirichoke T, Schroder H, Gerzer R, and Stasch JP (1999) Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide and carbon monoxide. J Mol Med 77:14-23.
19. Hwang TL, Hung HW, Kao SH, Teng CM, Wu CC, and Cheng SJ (2003) Soluble guanylyl cyclase activator YC-1 inhibits human neutrophil functions through a cGMP-independent but cAMP-dependent pathway. Mol Pharmacol 64:1419-1427.
20. Ko FN, Wu CC, Kuo SC, Lee FY, and Teng CM (1994) YC-1, a novel activator of platelet guanylate cyclase. Blood 84:4226-4233.
21. Koglin M and Behrends S (2003) A functional domain of the α1 subunit of soluble guanylyl cyclase is necessary for activation of the enzyme by nitric oxide and YC-1 but is not involved in heme binding. J Biol Chem 278:12590-12597.
22. Lucas KA, Pitari GM, Kazerounian S, Ruiz-Stewart I, Park J, Schulz S, Chepenik KP, and Waldman SA (2000) Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 52:375-414.
23. Moncada S, Palmer RM, and Higgs EA (1991) Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev 43:109-142.
24. Mullershausen F, Russwurm M, Friebe A, and Koesling D (2004) Inhibition of phosphodiesterase type 5 by the activator of nitric oxide-sensitive guanylyl cyclase BAY 41-2272. Circulation 109:1711-1713.
25. Mülsch A, Bauersachs J, Schafer A, Stasch JP, Kast R, and Busse R (1997) Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br J Pharmacol 120:681-689.
26. Murphy ME and Brayden JE (1995) Nitric oxide hyperpolarizes rabbit mesenteric arteries via ATP-sensitive potassium channels. J Physiol 486:47-58.
27. National Research Council (1996) Guide for the Care and Use of Laboratory Animals. National Academy Press, Washington, DC.
28. Parker JO (1989) Nitrate tolerance in angina pectoris. Cardiovasc Drugs Ther 2:823-829.
29. Priviero FBM, Baracat JS, Teixeira CE, Claudino MA, De Nucci G, and Antunes E (2005) Mechanisms underlying rabbit aorta relaxation by BAY 41-2272, a nitric oxide independent soluble guanylate cyclase activator. Clin Exp Pharmacol Physiol 32:728-734.
30. Rothermund L, Friebe A, Paul M, Koesling D, and Kreutz R (2000) Acute blood pressure effects of YC-1-induced activation of soluble guanylyl cyclase in normotensive and hypertensive rats. Br J Pharmacol 130:205-208.
31. Schrammel A, Behrends S, Schmidt K, Koesling D, and Mayer B (1996) Characterization of 1H-[1,2,4]oxadiazolo[4,3-α]quinoxalin-1-one as a heme-site inhibitor of nitric oxide-sensitive guanylyl cyclase. Mol Pharmacol 50:1-5.
32. Sperling RT and Creager MA (1999) Nitric oxide and pulmonary hypertension. Coron Artery Dis 10:287-294.
33. Stasch JP, Becker EM, Alonso-Alija C, Apeler H, Dembowsky K, Feurer A, Gerzer R, Minuth T, Perzborn E, Pleiss U, et al. (2001) NO-independent regulatory site on soluble guanylate cyclase. Nature (Lond) 410:212-215.
34. Straub A, Stasch JP, Alonso-Alija C, Benet-Buchholz J, Ducke B, Feurer A, and Furstner C (2001) NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 11:781-784.
35. Thomazzi SM, Moreira J, De Nucci G, and Antunes E (2005) Inhibitory effects on human eosinophil chemotaxis in vitro by BAY 41-2272, an activator of nitric oxide-independent site of soluble guanylate cyclase. Biochem Pharmacol 69:875-882.
36. 2+ entry by YC-1, an activator of soluble guanylyl cyclase, through a cyclic GMP-independent pathway in rat neutrophils. Biochem Pharmacol 62:679-684.
37. Wohlfart P, Malinski T, Ruetten H, Schindler U, Linz W, Schoenafinger K, Strobel H, and Wiemer G (1999) Release of nitric oxide from endothelial cells stimulated by YC-1, an activator of soluble guanylyl cyclase. Br J Pharmacol 128:1316-1322.
38. Wu CC, Ko FN, Kuo SC, Lee FY, and Teng CM (1995) YC-1 inhibited human platelet aggregation through NO-independent activation of soluble guanylate cyclase. Br J Pharmacol 116:1973-1978.